15.3 C
New York
Friday, September 29, 2023

BridgeBio Pharma Inc. (BBIO) Is Not Likely To Be The Same Tomorrow

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for BridgeBio Pharma Inc. (BBIO) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.23, or 0.78%, to $29.85. The BridgeBio Pharma Inc. has recorded 307,946 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Stocks Info

BridgeBio Pharma Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $29.62 and fluctuated between $30.57 as its day high and $29.29 as its day low. The current market capitalization of BridgeBio Pharma Inc. is $4.71B. A total of 1.6 million shares were traded on the day, compared to an average of 3.16M shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, BBIO has seen 3 BUY and 6 SELL insider trades, representing the acquisition of 151,004 and the disposition of 1,648,545 shares. Over the last 12 months, there were 14 BUYs and 35 SELLs from insiders. Insiders purchased 511,426 shares during that period but sold 3,103,042.

In the most recent transaction, Kumar Neil sold 51,552 shares of BBIO for 28.59 per share on Aug 17. After the transaction, the CEO and President now owns 4,813,197 company shares. In a previous transaction on Aug 17, STEPHENSON BRIAN C sold 22,683 shares at 28.59 per share. BBIO shares that Secretary, Treasurer & CFO owns now total 36,710.

Among the insiders who sold shares, VIKING GLOBAL INVESTORS LP disposed of 1,500,000 shares on Jul 18 at a per-share price of $35.00. This resulted in the 10% Owner holding 25,120,991 shares of BBIO after the transaction. In another insider transaction, Kumar Neil sold 51,552 shares at $14.01 per share on May 17. Company shares held by the CEO and President now total 4,813,197.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for BBIO in the last 3 months, the mean price target is $46.40 with high estimates of $60.00 and low estimates of $33.00. In terms of 52-week highs and lows, BBIO has a high of $36.36 and a low of $6.64.

As of this writing, BBIO has an earnings estimate of -$0.82 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.63 per share and a lower estimate of -$1. The company reported an EPS of -$0.92 in the last quarter, which was -10.80% lower than expectations of -$0.83.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. BBIO’s latest balance sheet shows that the firm has $787.51M in Cash & Short Term Investments as of fiscal 2021. There were $1.73B in debt and $130.13M in liabilities at the time. Its Book Value Per Share was -$8.48, while its Total Shareholder’s Equity was -$865.58M.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BBIO is Buy with a score of 4.70.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles